−$0.06 (0.23%) Thu · Closed $26.35
−$0.17 (0.65%) ☀ Pre-Market
Oct 30, 8:28 AM ET
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Latest: Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks Investment Research)
Headlines open the publisher's site.
Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about STOK?
Zacks Investment Research
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesStoke Therapeutics reported a Q3 loss of $1.08 per share, missing consensus estimates of $0.88 loss by 22.73%, though the company exceeded revenue expectations with $11.26 million versus estimated $8.29 million. The stock has underperformed the S&P 500 by 29.9% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Headlines open the publisher's site.
$STOK filed an 8-K with results (Item 2.02) at 4:05 PM ET on Thu, Oct 29.
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
